Biopharmaceuticals Market to Reach US$ 678 Billion by 2029 Growing at 9.8% CAGR Driven by Monoclonal Antibodies with 35% Highest Share Led by F. Hoffmann-La Roche Ltd. Pfizer Inc. Novartis AG and Emerging Player Samsung Biologics

The Biopharmaceuticals Market reached approximately US$ 418 billion in 2024 and is expected to grow to around US$ 678 billion by 2029, expanding at a CAGR of about 9.8% from 2025 to 2029, as global healthcare systems increasingly adopt advanced biologic therapies to address chronic diseases, rare disorders, and complex medical conditions.

Growth is driven by rising demand across key segments such as monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell-based therapies, supported by continuous innovation in biotechnology and precision medicine. Increasing prevalence of cancer, autoimmune diseases, diabetes, and infectious diseases is accelerating biologics adoption worldwide. Advancements in mRNA technology, biosimilars development, and personalized medicine approaches are further expanding treatment accessibility and affordability. Additionally, strong R&D investments, favorable regulatory pathways, expanding biomanufacturing capacity, and strategic collaborations among leading pharmaceutical and biotechnology companies continue to propel the global biopharmaceuticals market forward.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/biopharmaceuticals-market?sindhuri

Biopharmaceuticals Market: Competitive Intelligence
F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, Novartis AG, Merck & Co., Inc., AbbVie Inc., Amgen Inc., Sanofi S.A., GlaxoSmithKline plc, Bristol-Myers Squibb Company, and others.

The Biopharmaceuticals Market is strongly driven by leading global biotechnology and pharmaceutical companies such as F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, Novartis AG, and Merck & Co., Inc., which offer an extensive portfolio of monoclonal antibodies, recombinant proteins, vaccines, gene therapies, cell therapies, and biosimilars targeting oncology, immunology, infectious diseases, rare disorders, and metabolic conditions. These companies leverage advanced biologics manufacturing platforms, strong R&D pipelines, and global commercialization networks to strengthen their competitive positioning.

Market growth is fueled by the rising prevalence of chronic and autoimmune diseases, increasing demand for targeted and personalized therapies, rapid advancements in biologics and biosimilar development, expanding vaccine research, and significant investments in gene and cell therapy innovation. Additionally, supportive regulatory pathways, growing adoption of precision medicine, and technological progress in bioprocessing, single-use systems, and continuous manufacturing are accelerating production efficiency and scalability.

Key competitive advantages across the sector include Roche's leadership in oncology biologics and diagnostics integration; Pfizer's diversified biologics and vaccine portfolio; Johnson & Johnson's strong immunology and oncology pipeline; Novartis' expertise in advanced therapies including gene therapy; Merck & Co., Inc.'s immuno-oncology leadership; AbbVie's dominance in immunology biologics; Amgen's biologics and biosimilars expertise; Sanofi's vaccine and rare disease capabilities; GlaxoSmithKline plc's immunology and vaccine innovations; and Bristol-Myers Squibb Company's advanced oncology biologics pipeline.

Strategic focus areas include expansion of biosimilar portfolios, increased investment in mRNA and gene-editing technologies, strategic mergers and acquisitions, partnerships with biotech innovators, digitalization of biomanufacturing processes, and strengthening global supply chain resilience to meet rising biologics demand across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/biopharmaceuticals-market?sindhuri

Recent Key Developments - United States & North America
✅ June 2025: Pfizer Inc. expanded its U.S. biologics manufacturing capabilities to support next-generation monoclonal antibodies and mRNA-based therapeutics, strengthening domestic supply chain resilience.
✅ May 2025: Amgen Inc. advanced its biosimilars portfolio in North America, focusing on cost-effective biologic alternatives to improve patient access and reduce healthcare expenditure.
✅ 2025: Increasing adoption of cell and gene therapies across the U.S. accelerated investments in advanced bioprocessing facilities, cold chain logistics, and contract development and manufacturing organizations (CDMOs) to meet rising clinical and commercial demand.

Recent Key Developments - Japan & Asia-Pacific
✅ July 2025: Takeda Pharmaceutical Company Limited expanded its biologics R&D pipeline in Japan, prioritizing rare diseases and oncology-focused biopharmaceutical innovations.
✅ Early 2026: Samsung Biologics increased large-scale biologics manufacturing capacity in Asia-Pacific to serve global pharmaceutical partners and strengthen regional CDMO leadership.
✅ 2025: Growing regulatory harmonization and healthcare investments in China, India, South Korea, and Australia supported rapid expansion of biosimilars, recombinant proteins, and vaccine production capabilities across the region.

Recent Key Developments - Product & Technology Innovation
✅ 2025: Monoclonal Antibodies & Targeted Therapies: Advancements in antibody engineering and immune-oncology platforms enhanced treatment precision, efficacy, and safety across oncology and autoimmune indications.
✅ Cell & Gene Therapy Expansion: Increased commercialization of CAR-T therapies and gene-editing technologies improved treatment outcomes for rare and previously untreatable diseases.
✅ Advanced Bioprocessing & AI Integration: Adoption of single-use bioreactors, continuous manufacturing, and AI-driven drug discovery accelerated development timelines, optimized production efficiency, and reduced overall biologics manufacturing costs.

Major M&A / Strategic Deals (2025-2026)
1) GSK plc acquires 35Pharma (Feb 2026)
GSK signed an agreement to acquire all outstanding equity interests of Canada-based 35Pharma for ~$950 million in cash.

This transaction bolsters GSK's pipeline with HS235, a potential best-in-class investigational drug targeting pulmonary hypertension; phase I completed, with further trials planned.

The acquisition is part of GSK's strategy to expand into cardiopulmonary and metabolic-related treatments as existing drug patents expire.

2) Licensing & Global Rights Deal: Sino Biopharm & Sanofi (Mar 3 2026)
Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group granted Sanofi exclusive global rights to rovadicitinib (a JAK/ROCK inhibitor) for blood cancer and scarring.

Deal valued up to $1.53 billion (upfront + milestones).

3) Halozyme Acquires Surf Bio (Jan 2026)
Halozyme Therapeutics agreed to buy Surf Bio, a drug-delivery technology specialist, for up to ~$400 million to strengthen delivery platforms for biologics and injectable therapies.

This acquisition enhances capabilities in high-concentration subcutaneous administration important for biopharmaceutical products.

New Product Launches & Approvals
4) ZELSUVMITM (berdazimer) Launched (Jul 2025)
Ligand Pharmaceuticals partner Pelthos Therapeutics launched ZELSUVMITM, the first FDA-approved at-home topical treatment for water warts contagiosum (a contagious viral skin infection).
Ligand earns milestone payments and future royalties from global sales.

5) Clinical & R&D Pipeline Progress - BridgeBio Pharma
From official company releases:
Positive Phase 3 data reported for multiple genetic disease programs including:
BBP-418 in limb-girdle muscular dystrophy 2I/R9
Infigratinib in achondroplasia
Encaleret in autosomal dominant hypocalcemia type 1
NDAs planned for submission in 1H-2H 2026 with U.S. launches targeted later in 2026 / early 2027 if approved.
Pediatric and additional Phase 3 studies also being initiated.

R&D & Technological Advancements
6) Pipeline & Clinical Advancements
BridgeBio's late-stage portfolio now features several programs with positive pivotal outcomes, reducing traditional risk and accelerating submission timelines.
The commercial launch of Attruby® (acoramidis) in 2025 reported significant revenue and uptake marking a real-world advance in transthyretin amyloid cardiomyopathy care.

7) Industry-wide Deal & Pipeline Trends
Dealmaking remains a strategic response to funding challenges and shrinking exclusivities across the industry, pushing companies to replenish pipelines via acquisitions, licensing, and partnerships.

8) Contract Manufacturing (R&D Support Growth)
Forecasts show significant growth in biopharmaceutical CDMO services, driven by biologics and advanced therapies demand indicating a broader technological and manufacturing shift in how biopharma R&D is operationalized

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=biopharmaceuticals-market?sindhuri

Segments Covered in the Biopharmaceuticals Market:
By Type
The market is segmented into monoclonal antibodies (35%), recombinant proteins (18%), vaccines (15%), recombinant hormones (10%), purified proteins (8%), recombinant enzymes (6%), recombinant growth factors (5%), and synthetic immunomodulators (3%).Monoclonal antibodies dominate due to their strong efficacy in targeted therapies, particularly in oncology and autoimmune disorders. Recombinant proteins and vaccines hold significant shares driven by rising biologics approvals and preventive healthcare initiatives. Recombinant hormones and growth factors are widely used in metabolic and hormonal disorder management, while synthetic immunomodulators are gaining traction for immune-related diseases.

By Application
Applications comprise oncology (30%), autoimmune disorders (20%), disease prevention (15%), metabolic disorders (10%), hormonal disorders (10%), cardiovascular diseases (8%), and neurological diseases (7%).Oncology leads the segment due to increasing cancer prevalence and expanding biologics pipelines. Autoimmune disorders represent a major share owing to rising chronic inflammatory conditions. Disease prevention, driven by vaccine development and immunization programs, remains a strong contributor. Metabolic and hormonal disorders are expanding steadily with growing adoption of recombinant insulin and hormone therapies.

By Region
North America - 40% Share
North America dominates the market due to advanced healthcare infrastructure, high R&D investments, and strong presence of leading biopharmaceutical companies in the U.S. and Canada. Regulatory support and rapid biologics approvals further drive regional growth.

Europe - 25% Share
Europe holds a substantial share supported by strong biotechnology research, favorable reimbursement policies, and increasing demand for biosimilars across Germany, France, the U.K., Italy, and Spain.

Asia-Pacific - 22% Share
Asia-Pacific is witnessing rapid growth due to expanding healthcare access, increasing biologics manufacturing capacity, and government support for biotechnology development in China, India, Japan, and South Korea.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.